Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Go back to Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
(NASDAQ: ELDN) Delayed: 3.74 +0.02 (0.54%)
Previous Close $3.72    52 Week High
Open $3.84    52 Week Low
Day High $3.84    P/E N/A 
Day Low $3.62    EPS
Volume 614,335